Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CELC
CELC
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CELC News
Celcuity Inc. Options Trading Analysis
2d ago
NASDAQ.COM
Soleus Capital Increases Stake in Celcuity
2d ago
Fool
Celcuity Director Sells $2.4 Million in Shares via Indirect Transaction
Feb 06 2026
Fool
Celcuity to Participate in Biotech Summit 2026
Feb 04 2026
Newsfilter
Xpeng Inc Reports Disappointing Delivery Numbers, Stock Drops
Feb 02 2026
Benzinga
Celcuity (CELC) Receives FDA Priority Review for Gedatolisib, Target Action Date July 17, 2026
Jan 20 2026
seekingalpha
Celcuity (CELC) Receives FDA Priority Review for Gedatolisib with Goal Date of July 17, 2026
Jan 20 2026
NASDAQ.COM
Celcuity Inc. Receives FDA Priority Review for Gedatolisib with PDUFA Goal Date of July 17, 2026
Jan 20 2026
Globenewswire
Oncolytics Biotech Fortifies IP Protection, Extends Pelareorep Commercial Runway to 2044
Jan 08 2026
Globenewswire
Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments
Dec 31 2025
NASDAQ.COM
The $100 Club - Did You Get in Early on the Triple-Digit Surge of ABVX, NUTX, BLTE…?
Dec 19 2025
NASDAQ.COM
RH Reports Robust Q3 Sales, Aligns with Canopy Growth, Tilray Brands, Frequency Electronics, and Other Major Stocks Rising on Friday
Dec 12 2025
Benzinga
Analyzing the Best-Performing Russell 2000 Stocks in Relation to the Zacks Rank
Dec 12 2025
NASDAQ.COM
Celcuity Updates Gedatolisib Clinical Data, Achieving 16.6 Months PFS
Dec 11 2025
Globenewswire
Celcuity Reports Updated Gedatolisib Data with 16.6 Months PFS in Phase 3 Trial
Dec 11 2025
Newsfilter
Celcuity (CELC) Price Target Raised by 11.17% to 108.57
Dec 06 2025
NASDAQ.COM
Show More News
